KL
Lauper, Kim
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Reply | Arthritis & rheumatology |  | 2025 | 11 | 0 | ||
| From forgotten to frontline : the new era of crystal diseases ? | ARP rheumatology |  | 2025 | 31 | 75 | ||
| Défis dans la prise en charge des arthrites microcristallines | Revue médicale suisse | | 2025 | 22 | 0 | ||
| Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study) | Arthritis & rheumatology | | 2025 | 91 | 106 | ||
| Trends and influences in women authorship in randomised controlled trials in rheumatology : a comprehensive analysis of all published RCTs from 2009 to 2023 | RMD open | | 2025 | 48 | 57 | ||
| Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | | 2025 | 51 | 0 | ||
| Rhumatologie : ce qui a changé en 2023 | Revue médicale suisse | | 2024 | 55 | 49 | ||
| Rhumatologie en crise : repenser la formation et les soins face à un défi croissant | Revue médicale suisse | | 2024 | 35 | 67 | ||
| Large language models for accurate disease detection in electronic health records : the examples of crystal arthropathies | RMD open | | 2024 | 33 | 121 | ||
| Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study) | Annals of the rheumatic diseases | | 2024 | 99 | 87 | ||
| Development and validation of a self-updating gout register from electronic health records data | RMD open | | 2024 | 103 | 217 | ||
| A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs : Establishing a Framework to Create a "Safety Checklist" | Drug safety | | 2024 | 35 | 0 | ||
| Douleur monoarticulaire aiguë non traumatique | Revue médicale suisse | | 2024 | 89 | 0 | ||
| Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs : does line of therapy matter ? | Rheumatology | | 2024 | 31 | 155 | ||
| Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces : results from an international survey | RMD open | | 2024 | 41 | 62 | ||
| Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA | BMJ open | | 2024 | 137 | 128 | ||
| Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | | 2024 | 103 | 146 | ||
| 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | | 2024 | 69 | 2,260 | ||
| Polyarthrite rhumatoïde | Revue médicale suisse | | 2024 | 51 | 72 | ||
| Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study | Frontiers in medicine | | 2023 | 69 | 109 | ||
| Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab | RMD open | | 2023 | 86 | 47 | ||
| A potential role for chlamydial infection in rheumatoid arthritis development | Rheumatology | | 2023 | 93 | 230 | ||
| Use of complementary medicine and its association with SARS-CoV-2 vaccination during the COVID-19 pandemic : a longitudinal cohort study | Swiss medical weekly | | 2023 | 68 | 165 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the rheumatic diseases | | 2023 | 262 | 333 | ||
| The longitudinal study of subjective wellbeing and absenteeism of healthcare workers considering post-COVID condition and the COVID-19 pandemic toll | Scientific reports | | 2023 | 155 | 39 | ||
| Treatment for rheumatoid arthritis: Insights from real-life data | | 2023 | 144 | 55 | |||
| Poussées de la polyarthrite rhumatoïde | Revue médicale suisse | | 2023 | 107 | 116 | ||
| Prise en charge hospitalière de la goutte | Revue médicale suisse | | 2023 | 35 | 248 | ||
| Rhumatologie : ce qui a changé en 2022 | Revue médicale suisse | | 2023 | 155 | 104 | ||
| Prevalence of Post-COVID Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status | Clinical infectious diseases | | 2023 | 171 | 266 | ||
| Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumab | JAMA neurology | | 2022 | 250 | 186 | ||
| EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology | Annals of the rheumatic diseases | | 2022 | 211 | 81 | ||
| One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals | Journal of internal medicine | | 2022 | 274 | 130 | ||
| After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries | Annals of the rheumatic diseases | | 2022 | 269 | 536 | ||
| Nouveautés en médecine 2021 - Rhumatologie | Revue médicale suisse | | 2022 | 297 | 270 | ||
| Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study | Annals of the rheumatic diseases | | 2022 | 295 | 138 | ||
| 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases | Annals of the rheumatic diseases | | 2022 | 124 | 2,979 | ||
| Prévention vaccinale chez les patients avec des maladies rhumatismales | Revue médicale suisse | | 2022 | 112 | 151 | ||
| Global epidemiology of rheumatoid arthritis | Nature reviews. Rheumatology | | 2022 | 367 | 1 | ||
| Extent of and reasons for discontinuation and nonpublication of interventional trials on connective tissue diseases: an observational study | Arthritis care & research | | 2022 | 271 | 293 | ||
| Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study | Clinical infectious diseases | | 2022 | 236 | 164 | ||
| Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration | Annals of the rheumatic diseases | | 2022 | 340 | 102 | ||
| Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases | Frontiers in immunology | | 2022 | 206 | 117 | ||
| The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University Hospital | Preventive medicine reports | | 2022 | 256 | 143 | ||
| The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization | Scientific reports | | 2022 | 223 | 121 | ||
| Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the eustar database | Rheumatology | | 2021 | 279 | 459 | ||
| Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis | BMJ Open | | 2021 | 356 | 224 | ||
| How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies | Expert review of clinical immunology | | 2021 | 170 | 389 | ||
| Publishing in 2@84 | Annals of the Rheumatic Diseases | | 2021 | 193 | 0 | ||
| Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology | RMD open | | 2021 | 266 | 177 | ||
| EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future | RMD open | | 2021 | 227 | 178 | ||
| Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic | Annals of the Rheumatic Diseases | | 2021 | 212 | 341 | ||
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | | 2021 | 249 | 0 | ||
| The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus | Autoimmunity Reviews | | 2021 | 243 | 0 | ||
| Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab | RMD open | | 2021 | 265 | 126 | ||
| Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study | RMD Open | | 2020 | 317 | 191 | ||
| Back pain occurrence and treatment-seeking behavior among nurses: the role of work-related emotional burden | Quality of Life Research |  | 2020 | 374 | 1 | ||
| Petites molécules dans la polyarthrite rhumatoïde | Revue médicale suisse | | 2020 | 292 | 3 | ||
| Response to: 'When binary and continuous responses disagree' by Dr Ouyang | Annals of the Rheumatic Diseases | | 2020 | 323 | 2 | ||
| Predictive factors of treatment persistence in rheumatoid arthritis | Joint, Bone, Spine | | 2020 | 431 | 720 | ||
| Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | | 2019 | 375 | 0 | ||
| Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? | RMD Open | | 2019 | 336 | 165 | ||
| Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis | Seminars in Arthritis and Rheumatism | | 2019 | 322 | 252 | ||
| Associations of regrets and coping strategies with job satisfaction and turnover intention: international prospective cohort study of novice healthcare professionals | Swiss Medical Weekly | | 2019 | 438 | 521 | ||
| Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration | Annals of the Rheumatic Diseases | | 2018 | 461 | 1 | ||
| Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries | RMD Open | | 2018 | 355 | 192 | ||
| Le risque cardiovasculaire dans la polyarthrite rhumatoïde, la spondylarthrite axiale et le rhumatisme psoriasique | | 2018 | 792 | 495 | |||
| Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | | 2018 | 441 | 493 | ||
| The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | | 2017 | 633 | 3 | ||
| Cardiovascular risk in patients with rheumatoid arthritis | Seminars in Immunopathology | | 2017 | 461 | 0 | ||
| Traitement de fond de la polyarthrite rhumatoïde | Revue médicale suisse | | 2014 | 296 | 2 | ||
| Hépatite auto-immune | Revue médicale suisse | | 2013 | 323 | 1 |
